FundaMental Pharma
Phase 2The orally bioavailable clinical candidate FMP374 is ready for IND-enabling studies and no showstopper has been identified in preclinical studies supporting candidate nomination. Since the molecule works on a clinically validated drug target and pathway, the development program is substantially de-risked, resulting in a highly favorable predicted probability of success.
Private Company
Total funding raised: $23.5M
About
The orally bioavailable clinical candidate FMP374 is ready for IND-enabling studies and no showstopper has been identified in preclinical studies supporting candidate nomination. Since the molecule works on a clinically validated drug target and pathway, the development program is substantially de-risked, resulting in a highly favorable predicted probability of success.